Recursion Pharmaceuticals
RXRX
RXRX
158 hedge funds and large institutions have $841M invested in Recursion Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 55 increasing their positions, 32 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
0.66% more ownership
Funds ownership: 68.1% → 68.76% (+0.66%)
12% less capital invested
Capital invested by funds: $953M → $841M (-$111M)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Holders
158
Holding in Top 10
5
Calls
$633K
Puts
$383K
Top Buyers
| 1 | +$5.84M | |
| 2 | +$3.43M | |
| 3 | +$3.38M | |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$3.18M |
| 5 |
Citigroup
New York
|
+$3.04M |
Top Sellers
| 1 | -$9.99M | |
| 2 | -$7.4M | |
| 3 | -$1.86M | |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1.29M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.1M |